Litcius/Paper detail

Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1–2 study

Toby A. Eyre, Anna Schuh, William G. Wierda, Jennifer R. Brown, Paolo Ghia, John M. Pagel, Richard R. Furman, Jean Cheung, Ahmed Hamdy, Raquel Izumi, Priti Patel, Min Hui Wang, Yan Xu, John C. Byrd, Peter Hillmen

2021The Lancet Haematology60 citationsDOIOpen Access PDF

Topics & Concepts

MedicineInternal medicinePopulationDiffuse large B-cell lymphomaProgression-free survivalGastroenterologyClinical endpointPhases of clinical researchAggressive lymphomaOncologyClinical trialLymphomaSurgeryChemotherapyRituximabEnvironmental healthChronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentHER2/EGFR in Cancer Research
Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1–2 study | Litcius